PERSON – Page 23

Boston Pharmaceuticals Achieves Phase 2 Success with Efimosfermin Alfa for MASH Treatment, Paving Way for Pivotal Trials

6 months ago talkbio0Tagged Analog, BOS-580, Clinical Trials, efimosfermin alfa, fibroblast growth factor 21, Liver diseases, MASH, metabolic dysfunction-associated steatohepatitis, Nonalcoholic Steatohepatitis, Phase 2, trials

Efimosfermin alfa (BOS-580), Metabolic dysfunction-associated steatohepatitis (MASH), Non-alcoholic steatohepatitis (NASH), Phase 2 clinical trials, FGF21 analogue, Liver disease treatment, Pivotal trials

Sensei Biotherapeutics Announces Major Restructuring: 46% Workforce Reduction and Closure of Rockville Research Site

6 months ago talkbio0Tagged Clinical Development, Organization administrative structures, Research Site Closure, restructuring, Sensei Biotherapeutics, SNS-101

Sensei Biotherapeutics, workforce reduction, research site closure, organizational restructuring, SNS-101 clinical development

FDA Approves PTC Therapeutics’ Kebilidi, the First Gene Therapy Delivered Directly to the Brain for AADC Deficiency

6 months ago talkbio0Tagged Approved, Brain-Delivered Therapy, DDC gene, Deficiency, factor IX, gene therapy, Hereditary Diseases, Kebilidi, United States Food and Drug Administration

PTC Therapeutics, Kebilidi, Gene Therapy, AADC Deficiency, FDA Approval, Brain-Delivered Therapy, Rare Genetic Disorder

Allogene Halts Leukemia CAR-T Trial Enrollment Due to Breyanzi Competition

6 months ago talkbio0Tagged Allogene, Breyanzi, CAR-T, cema-cel, Clinical Trials, leukemia, Myers, squibb

Allogene, CAR-T therapy, leukemia, Breyanzi, Bristol Myers Squibb, cema-cel, clinical trials

Adaptimmune Prepares for Next FDA Submission Following Success in Pivotal Sarcoma Study

6 months ago talkbio0Tagged Adaptimmune, Afami-cel, Cancer Therapeutic Procedure, Cell Therapy, Sarcoma, Submission, synovial sarcoma, United States Food and Drug Administration

Adaptimmune, FDA submission, sarcoma study, afami-cel, lete-cel, cell therapy, synovial sarcoma, cancer treatment

BioNTech Acquires Biotheus for $800M to Enhance Oncology Strategy with Promising Bispecific Antibody

6 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, BioNTech, Biotheus, BNT327/PM8002, Cancer Therapeutic Procedure, Neoplasms, PD-L1, Vascular Endothelial Growth Factor A

BioNTech, Biotheus, oncology, bispecific antibody, BNT327/PM8002, PD-L1, VEGF-A, cancer treatment, acquisition

BioNTech Invests $800M in PD-L1xVEGF-A Bispecific, Aiming to Challenge Keytruda Dominance

6 months ago talkbio0Tagged BioNTech, Biotheus, bispecific, Drug Industry, Immunotherapy for cancer, Keytruda, PD-L1xVEGF-A

BioNTech, Keytruda, PD-L1xVEGF-A bispecific, Biotheus, cancer immunotherapy, pharmaceutical industry

Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A

6 months ago talkbio0Tagged Biopharma, Health care facility, Jr., M&A, Robert F. Kennedy Jr., Transplant Registry Unified Management Program, United States Food and Drug Administration

Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.

Genmab Streamlines Portfolio by Cutting Early-Stage Oncology Assets

6 months ago talkbio0Tagged Early-stage, Genmab, Neoplasms, Optimization, Phase, portfolio

Genmab, oncology, early-stage candidates, portfolio optimization, Phase 3 projects

Sarepta Therapeutics Halts Development of Vesleteplirsen, a Next-Generation Exon-Skipping Therapy for Duchenne Muscular Dystrophy

6 months ago talkbio0Tagged Duchenne, Exon-Skipping Therapy, Feedback - system communication, Landscapes, Muscular Dystrophy, Muscular Dystrophy, Duchenne, SRP-5051, United States Food and Drug Administration, Vesleteplirsen

Sarepta Therapeutics, Vesleteplirsen (SRP-5051), Duchenne Muscular Dystrophy (DMD), Exon-Skipping Therapy, FDA Feedback, Therapeutic Landscape